Skip to main content

Table 1 Clinicopathological features and the expression of nucleolin in 130 hepatocellular carcinoma patients

From: Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

Clinicopathological features

Case

Nucleolin expression frequency (n,%)

P

High

Low

Age (years)

    

≤50

72

40 (55.56)

32 (44.44)

NS

>50

58

28 (48.28)

20 (51.72)

Gender

    

Male

96

58 (60.42)

42 (39.58)

NS

Female

34

20 (58.82)

14 (41.18)

Serum AFP

    

Positive

72

58 (80.56)

14 (19.44)

0.008

Negative

58

20 (34.48)

38 (65.52)

Tumor stage

    

T1

23

0 (0)

23 (100.00)

0.001

T2

40

23 (57.50)

17 (42.50)

T3

52

40 (76.92)

12 (23.08)

T4

15

15 (100.00)

0 (0)

Tumor grade

    

G1

31

12 (38.71)

19 (61.29)

0.02

G2

76

48 (63.16)

28 (36.84)

G3

23

18 (78.26)

5 (21.74)

Growth pattern

    

Trabecular

101

59 (58.42)

42 (41.58)

NS

Nontrabecular

29

19 (65.52)

10 (34.48)

Cirrhosis

    

Yes

86

50 (58.14)

36 (41.86)

NS

No

44

28 (63.64)

16 (36.46)

Underlying liver disease

    

Alcoholic

25

10 (40.00)

15 (60.00)

NS

Hepatitis B

49

28 (57.14)

21 (42.86)

Hepatitis C

35

28 (80.00)

7 (20.00)

Unknown

21

12 (57.14)

9 (42.86)

  1. Note: `NS' refers to the differences among groups have no statistical significance.